

## COMMUNICATION

 View Article Online  
 View Journal | View Issue


 Cite this: *Org. Biomol. Chem.*, 2024, **22**, 496

 Received 16th November 2023,  
 Accepted 20th December 2023

DOI: 10.1039/d3ob01862h

rsc.li/obc

# Bi(OTf)<sub>3</sub>-promoted cascade annulation of hydroxy-pyranones and unsaturated $\gamma$ -ketoesters for the construction of polycyclic bridged pyrano-fuopyranones†

 Akshay B. Rathod,<sup>a,b</sup> Balasaheb R. Borade,<sup>a,b</sup> Pooja I. Sambherao<sup>a,b</sup> and Ravindar Kontham <sup>\*a,b</sup>

An efficient protocol for constructing complex three dimensional polycyclic bridged chromano-fuopyranones and pyrano-fuopyranones (closely related to bioactive natural products) *via* bismuth (iii)-catalyzed cascade annulation of hydroxy-pyranones and unsaturated  $\gamma$ -ketoesters is presented. This process involves intermolecular Michael addition, intramolecular hemiketalization, lactonization, formation of one C–C bond and two C–O bonds, rings, and contiguous stereocenters.

Chromane and pyrone-fused fuo-pyranones are found in natural products and pharmaceuticals, with various applications, including cellular imaging and solar cells.<sup>1</sup> For instance, (+)-penicipyrene, isolated from the fungus *Penicillium sp.* PSU-F44, exhibits antibacterial activity.<sup>2</sup> On the other hand, (–)-tenuipyrene was isolated from the entomopathogenic fungus *Isaria tenuipes* in the presence of epigenetic modifying agents, including a histone deacetylase inhibitor and a DNA methyltransferase inhibitor.<sup>3</sup> Pyripyropenes A–D, isolated from *Aspergillus fumigatus* FO-1289, are potent acyl-CoA inhibitors and stand out as the most potent naturally derived ACAT inhibitors, with nanomolar IC<sub>50</sub> values in rat liver microsomes.<sup>4</sup> Arisugacin functions as an acetylcholinesterase (AChE) inhibitor, while territrem A–C, with a pyranopyran skeleton, selectively inhibit human AChE (Fig. 1).<sup>5,6</sup> The intriguing aspects of these features have led to a sustained emphasis on developing efficient methodologies for synthesizing chroman/pyrone-derived scaffolds in synthetic chemistry.<sup>7</sup>

In this context, Tong and co-workers disclosed an expedited strategy for constructing pyrone-tethered [5,6]-spiroketals through amberlyst-15 promoted intermolecular annulative cyclo-ketalization (proceeds through Michael addition/hemiketalization and spiroketalization sequence) of 4-hydroxy 6-methyl-2-pyrone with  $\alpha,\beta$ -unsaturated 1,3-diketones. This

strategy was successfully employed in their biomimetic total synthesis of (–)-penicipyrene and (–)-tenuipyrene (entry 1a, Scheme 1).<sup>8</sup> In 2020, Zhang's group reported an organocatalytic asymmetric reaction involving 4-hydroxycoumarins and 2-hydroxy cinnamaldehydes. This reaction proceeded *via* conjugate addition, facilitating the construction of chiral bridged acetals (Scheme 1).<sup>9</sup>

In continuation of our interest in developing atom and step-efficient cascade annulation reactions utilizing Lewis acid catalysis,<sup>10</sup> recently, we unveiled a Fe(III)-catalyzed cascade annulation involving electron-rich hydroxyarenes and suitably functionalized unsaturated  $\gamma$ -ketoesters.<sup>11</sup> This approach enabled the synthesis of polycyclic bridged/fused 2-chromanol lactones, introducing three new bonds, stereocenters, and new rings into the molecular framework (entry 1b, Scheme 1).<sup>12</sup> Herein, we report the unprecedented synthesis of polycyclic bridged chromano (pyrano)-fuopyranones 3/5 (which represent lactone analogs akin to penicipyrene and tenuipyrene) through bismuth(III)-catalyzed<sup>10,12</sup> cascade annulation of chromenones/hydroxy-pyranones 1/4 and unsaturated  $\gamma$ -ketoesters 2 (entry 2, Scheme 1).




Fig. 1 Natural products containing fused pyrano-fuopyran moiety.


<sup>a</sup>Organic Chemistry Division, CSIR-National Chemical Laboratory Dr Homi Bhabha Road, Pune-411008, India. E-mail: k.ravindar@ncl.res.in

<sup>b</sup>Academy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India


† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3ob01862h>

## 1. Previous work


## a. Total synthesis of tenuipyron and penicipyron



## b. From pre-constructed Keto ester (our previous work)



## 2. This work



**Scheme 1** Previous cascade annulation approaches to access furo-pyr-anones, and our present work.

We initiated the reaction optimization studies by selecting commercially available 4-hydroxycoumarin (**1a**) and known<sup>12</sup> unsaturated  $\gamma$ -ketoester **2a** (featuring cyclohexenone Michael acceptor) as substrates (Table 1). Drawing from our previous research and guided by literature examples involving Brønsted acid catalysis in Michael addition-induced cascade processes, we began by assessing various catalysts such as TfOH, TFA, *p*-TSA, PPTS, and Amberlyst-15 (used at 20 mol%) in combination with DCE as the reaction medium. These initial reactions did not progress at room temperature (27 °C). Encouragingly, we found that TfOH, TFA, and amberlyst-15 demonstrated varying degrees of activity, leading to the formation of the desired annulation product **3aa** with isolated yields of 41%, 24%, and 17% for product **3aa**, respectively at 80 °C (entries 1–5 in Table 1). The product **3aa** was confirmed through <sup>1</sup>H and <sup>13</sup>C NMR (DEPT) and HRMS analyses and further verified by comparing the obtained data to our previously reported findings for similar bridged ketal-lactones (Table 1).<sup>12</sup>

Subsequently, our focus shifted towards investigating the impact of various Lewis acids on this annulation process.<sup>14,15</sup> To this end, we initially employed the conditions we had previously identified<sup>12</sup> 20 mol% of Fe(OTf)<sub>3</sub> in DCE at 80 °C. Under these conditions, **3aa** was obtained in an improved yield

**Table 1** Optimization studies<sup>a</sup>

Entry	Catalyst	Solvent	Yield <sup>b</sup> (%)
1	TfOH	DCE	41
2	TFA	DCE	24
3	PTSA	DCE	– <sup>c</sup>
4	PPTS	DCE	– <sup>c</sup>
5	Amberlyst-15	DCE	17
6	Fe(OTf) <sub>3</sub>	DCE	51
7	AgOTf	DCE	24
8	Cu(OTf) <sub>2</sub>	DCE	37
9	Sc(OTf) <sub>3</sub>	DCE	20
10	BF <sub>3</sub> ·Et <sub>2</sub> O	DCE	18
11	Bi(OTf) <sub>3</sub>	DCE	70
12	Bi(OTf) <sub>3</sub>	PhF	76
13	No catalyst	PhF	– <sup>c</sup>


<sup>a</sup> Unless otherwise specified the reaction was performed with **1a** (0.55 mmol), **2a** (0.55 mmol), catalyst (20 mol%), and in indicated solvent (anhydrous, 2 mL) at 80 °C. <sup>b</sup> Isolated yield of **3aa**. <sup>c</sup> No conversion was observed.

of 51% in an 8-hour reaction (entry 6, Table 1). Expanding our exploration, we subjected the reaction to different metal triflates catalysts including AgOTf, Cu(OTf)<sub>2</sub>, Sc(OTf)<sub>3</sub>, and BF<sub>3</sub>·Et<sub>2</sub>O. However, these alternative Lewis acids resulted in comparably lower yields of **3aa** when compared to Fe(OTf)<sub>3</sub> (entries 7–10). The reaction using 20 mol% of Bi(OTf)<sub>3</sub> in DCE at 80 °C resulted in an improved yield of 70% (entry 11). Interestingly, when employing PhF as the solvent, the reaction furnished **3aa** with a favorable outcome of 76% and exhibited a clean thin-layer chromatography (TLC) profile (entry 12).


As anticipated, the reaction failed to progress in the absence of the catalyst, leading to full recovery of both annulation partners **1a** and **2a** (entry 13) (Table 1). Notably, Bi(OTf)<sub>3</sub> displayed moderate activity when PhCl, THF, and CH<sub>3</sub>CN were used as solvents (entries 1–3, Table S1†), while its activity ceased when solvents like DMF, toluene, MeOH, and EtOH were employed (entries 4–7, Table S1†).<sup>13</sup> Further alteration of reaction parameters like molar ratios of substrates and catalyst (Bi(OTf)<sub>3</sub> loading (5 and 10 mol%, entries 8 and 9, Table S1†) did not lead to discernible improvement.<sup>13</sup> Ultimately, it was determined that the ideal conditions for this cascade annulation reaction were the use of Bi(OTf)<sub>3</sub> (20 mol%) in PhF at 80 °C (entry 12, Table 1).

With the optimal reaction condition in hand, we next evaluated the scope and generality of this cascade reaction concerning the 4-hydroxy pyranones (**1**) and unsaturated  $\gamma$ -ketoesters **2** possessing diverse substituents (Scheme 2).


The reaction involving 4-hydroxy-2H-chromen-2-ones possessing phenyl,  $\alpha$ -naphthyl, and  $\beta$ -naphthyl segments (**1a–1c**) proceeded well with cyclohexenone-tethered ketoester **2a**, and delivered corresponding polycyclic adducts **3aa–3ca** in good yields ranging from 61% to 76%. Moving forward, hydroxy-chromenones containing electron-donating substituents



## a. Using 4-hydroxycoumarins (1)





## b. Using 4-hydroxy-2-pyrones (4)



**Scheme 2** Scope of the cascade annulation of hydroxy-chromenones/hydroxy-pyranones (1/4) with cycloalkenone-tethered unsaturated  $\gamma$ -ketoesters (2).

(–OMe, –Me) **1d**, **1e** and **1f** were treated with **2a**, which furnished products **3da**, **3ea**, and **3fa**. Halogenated substrates **1** also reacted well and delivered adducts **3ua**, **3ga**, and **3ha** in good yields. Conversely, hydroxy-chromenones having electron-withdrawing substituents (–NO<sub>2</sub>) did not engage in the reaction with **2a**, and both starting materials were recovered. Interestingly, cycloheptenone bearing ketoester **2b** also participated well in the annulation with hydroxy-2H-chromen-2-one (**1a**), culminating in the formation of product **3ab** with a yield of 73% (entry a, Scheme 3). Whereas cyclopentenone-bearing ketoester **2c** failed to participate in the annulation.<sup>13</sup>




**Scheme 3** Scope of the cascade annulation of hydroxy-chromenones/hydroxy-pyranones (1/4) with acyclic enone-tethered unsaturated  $\gamma$ -ketoesters (6).

Expanding on our protocol, we explored the reactions of 6-substituted hydroxy-pyranones **4** using optimized conditions. Encouragingly, diverse substituents at C-6 (–methyl, –i-Pr, –cyclopropyl, cyclohexyl, phenyl,  $\alpha$ -naphthyl, anisyl, tolyl, *p*-fluoro-phenyl, *p*-chloro-phenyl) successfully reacted with cyclohexenone-tethered ketoester **2a**, yielding (pyrano)-furofuranones adducts **5aa–5ja** in yields ranging from 45% to 85%. Additionally, pyranones derived from heteroarenes (thiophenyl and *N*-tosyl-indolyl) produced **5ka** and **5la** in yields of 54% and 67%, respectively. Notably, C-5 substituted pyranones did not engage in this annulation (entry b, Scheme 2).<sup>13</sup> Next, we demonstrated the practicality and scalability of this protocol by conducting reactions on a 1.0-gram scale of **1a** and **4a**, resulting in good yields of **3aa** and **5aa**. The relative stereochemistry of these adducts was assigned based on our previous report,<sup>11</sup> NOE correlations of **5ea**, and analogy.<sup>13</sup>

Encouraged by these results, we investigated the reactivity of unsaturated  $\gamma$ -ketoesters **6**, which contain an acyclic enone and diverse substituents (cyclohexyl, decyl, phenyl, cyclopentyl), with hydroxy chromenone (**1a**) and various pyranones (**4**). All these reactions proceeded well, delivering the corresponding chromenone-derived adducts (**7aa** and **7ab**), as well as pyrone-tethered adducts (**8aa–8ac**, **8ed**, **8ec**, **8ic** and **8mc**), in moderate yields in 24 hours. Interestingly, the C-5 substituted pyrone (**4n**) also participated in this annulation, yielding **8nc** in a 38% yield (Scheme 3).

Based on previous reports from our group<sup>11</sup> and others,<sup>8,9</sup> as well as the results obtained in this study, we propose a plausible mechanistic sequence for this cascade annulation, outlined in Scheme 4.<sup>8,10–12</sup> The Bi(III)-activated enone partners **2/6**, trigger the Michael addition with the electron-rich hydroxy-chromen(pyran)-one **1/4**, resulting in the formation of intermediate **A**. Subsequent intramolecular hemiketalization of **A** leads to the formation of intermediate **B**. This hemiketal intermediate **B** then undergoes Bi(III)-facilitated lactonization, yielding chromano(pyran)-furofuranones **3/5/7/8**.



**Scheme 4** Plausible reaction mechanism.

In conclusion, we have developed a novel protocol for synthesizing intricate polycyclic bridged chromano-fuopyranones and pyrano-fuopyranones, which are relevant to bio-active natural compounds. This approach involves the Bi(III)-catalyzed cascade annulation of hydroxy-chromenones/hydroxy-pyranones with unsaturated  $\gamma$ -ketoesters. The reaction pathway encompasses a sequence of transformations, including Michael addition, hemiketalization, and lactonization. Our method has successfully yielded diverse three-dimensional polycyclic adducts akin to natural products such as tenuipyrone and penicipyron, achieving favorable yields. Notably, the practicality of this methodology has been demonstrated through gram-scale experiments. Ongoing efforts are directed toward exploring the biological activities of these synthesized products, and we anticipate publishing these findings in due course.

## Author contributions

R. K. conceived the project and directed the research work. A. B. R, B. R. B, and P. I. S conducted synthetic experiments, analyzed data, and prepared ESI. All authors commented on the manuscript and the ESI.†

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

We express our sincere gratitude for the funding received from the SERB (Science & Engineering Research Board), New Delhi, India (Grant No. CRG/2020/001875). Additionally, B. R. B. would like to thank UGC-India, and P. I. S. extends appreciation to DST-Inspire for granting the Senior Research Fellowships (SRF).

## References

- (a) J. R. S. Hoult and M. Payá, *Gen. Pharmacol.*, 1996, **27**, 713–722; (b) M. Sarmah, K. Chutia, D. Dutta and P. Gogoi, *Org. Biomol. Chem.*, 2022, **20**, 55–72; (c) G. Signore, R. Nifosi, L. Albertazzi, B. Storti and R. Bizzarri, *J. Am. Chem. Soc.*, 2010, **132**, 1276–1288; (d) K. G. Reddie, W. H. Humphries, C. P. Bain, C. K. Payne, M. L. Kemp and N. Murthy, *Org. Lett.*, 2012, **14**, 680–683, and references cited therein.
- K. Trisuwan, V. Rukachaisirikul, Y. Sukpondma, S. Phongpaichit, S. Preedanon and J. Sakayaroj, *Chem. Pharm. Bull.*, 2009, **57**, 1100–1102.
- T. Asai, Y. M. Chung, H. Sakurai, T. Ozeki, F. R. Chang, K. Yamashita and Y. Oshima, *Org. Lett.*, 2012, **14**, 513–515.
- T. Ohshiro, D. Matsuda, K. Sakai, C. Degirolamo, H. Yagyu, L. L. Rudel, S. Omura, S. Ishibashi and H. Tomoda, *Arterioscler. Thromb. Vasc. Biol.*, 2011, **31**, 1108–1115.
- T. Sunazuka, M. Handa, K. Nagai, T. Shirahata, Y. Harigaya, K. Otoguro, I. Kuwajima and S. Omura, *Org. Lett.*, 2002, **4**, 367–369.
- (a) F. C. Peng, C. M. Chiou and K. H. Ling, *J. Nat. Prod.*, 1992, **55**, 251–255; (b) J. Cheung, E. N. Gary, K. Shiomi and T. L. Rosenberry, *ACS Med. Chem. Lett.*, 2013, **4**, 1091–1096.
- (a) M. Lončarić, D. G. Sokač, S. Jokić and M. Molnar, *Biomolecules*, 2020, **10**, 151; (b) K. Szwaczko, *Inorganics*, 2022, **10**, 23; (c) S. Gulati, R. Singh and S. Sangwan, *RSC Adv.*, 2021, **11**, 29130–29155; (d) D. Dobler, M. Leitner, N. Moor and O. Reiser, *Eur. J. Org. Chem.*, 2021, 6180–6205, and references cited therein. (e) S. Y. Chen, Q. Li, X. G. Liu, J. Q. Wu, S. S. Zhang and H. Wang, *ChemSusChem*, 2017, **10**, 2360–2364; (f) Y. Liu, S. Lin, Y. Li, J. H. Xue, Q. Li and H. Wang, *ACS Catal.*, 2023, **13**, 5096–5103.
- (a) L. Song, H. Yao, L. Zhu and R. Tong, *Org. Lett.*, 2013, **15**, 6–9; (b) H. Yao, L. Song, Y. Liu and R. Tong, *J. Org. Chem.*, 2014, **79**, 8774–8785.
- X. Q. Zhang, X. J. Lv, J. P. Pei, R. Tan and Y. K. Liu, *Org. Chem. Front.*, 2020, **7**, 292–297.
- (a) D. A. Kambale, S. S. Thorat, M. S. Pratapure, R. G. Gonnade and R. Kontham, *Chem. Commun.*, 2017, **53**, 6641–6644; (b) S. S. Thorat, P. Kataria and R. Kontham, *Org. Lett.*, 2018, **20**, 872–875; (c) A. K. Nakate, M. S. Pratapure and R. Kontham, *Org. Biomol. Chem.*, 2018, **16**, 3229–3240; (d) D. A. Kambale, B. R. Borade and R. Kontham, *Org. Biomol. Chem.*, 2021, **19**, 6618–6622; (e) A. K. Nakate, S. S. Thorat, S. Jain, G. Rama Krishna, K. Vanka and R. Kontham, *Org. Chem. Front.*, 2022, **9**, 802–809; (f) Y. Mankad, S. S. Thorat, P. Das, G. Rama Krishna, R. Kontham and D. S. Reddy, *J. Org. Chem.*, 2022, **87**, 3025–3041; (g) D. A. Kambale, B. R. Borade, R. Vinodkumar and R. Kontham, *J. Org. Chem.*, 2023, **88**, 12597–12612.
- B. R. Borade, R. Nomula, R. G. Gonnade and R. Kontham, *Org. Lett.*, 2019, **21**, 2629–2633.
- (a) H. Gaspard-Iloughmane and C. Le Roux, *Eur. J. Org. Chem.*, 2004, 2517–2532; (b) T. Ollevier, *Org. Biomol. Chem.*, 2013, **11**, 2740–2755; (c) J. M. Bothwell, S. W. Krabbe and

- R. S. Mohan, *Chem. Soc. Rev.*, 2011, **40**, 4649–4707; (d) M. Magre and J. Cornella, *J. Am. Chem. Soc.*, 2021, **143**, 21497–21502; (e) E. Lopez, S. C. Thorp and R. S. Mohan, *Polyhedron*, 2022, **222**, 115765, and references cited therein.
- 13 See the ESI† for details.
- 14 (a) H. Yamamoto, *Lewis Acids in Organic Synthesis*, Wiley-VCH, 2008; (b) A. Corma and H. García, *Chem. Rev.*, 2003, **103**, 4307–4365; (c) Y. Yamamoto, *J. Org. Chem.*, 2008, **73**, 5210; (d) S. Kobayashi, M. Sugiura, H. Kitagawa and W. W. L. Lam, *Chem. Rev.*, 2002, **102**, 2227–2302.
- 15 (a) N. G. Turrini, R. C. Cioc, D. J. H. Van Der Niet, E. Ruijter, R. V. A. Orru, M. Hall and K. Faber, *Green Chem.*, 2017, **19**, 511–518; (b) P. Chen and S. Wang, *Tetrahedron*, 2012, **68**, 5356–5362; (c) S. Antoniotti, V. Dalla and E. Duñach, *Angew. Chem., Int. Ed.*, 2010, **49**, 7860–7888.